Copyright Reports & Markets. All rights reserved.

Global Hepatoma Cell Targeted Drug Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Hepatoma Cell Targeted Drug by Type
    • 1.3.1 Overview: Global Hepatoma Cell Targeted Drug Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Hepatoma Cell Targeted Drug Consumption Value Market Share by Type in 2024
    • 1.3.3 Sorafenib
    • 1.3.4 Lenvatinib
    • 1.3.5 Regorafenib
    • 1.3.6 Other
  • 1.4 Global Hepatoma Cell Targeted Drug Market by Application
    • 1.4.1 Overview: Global Hepatoma Cell Targeted Drug Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hospital
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Other
  • 1.5 Global Hepatoma Cell Targeted Drug Market Size & Forecast
  • 1.6 Global Hepatoma Cell Targeted Drug Market Size and Forecast by Region
    • 1.6.1 Global Hepatoma Cell Targeted Drug Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Hepatoma Cell Targeted Drug Market Size by Region, (2020-2031)
    • 1.6.3 North America Hepatoma Cell Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Hepatoma Cell Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Hepatoma Cell Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.6 South America Hepatoma Cell Targeted Drug Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Hepatoma Cell Targeted Drug Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 Bayer
    • 2.1.1 Bayer Details
    • 2.1.2 Bayer Major Business
    • 2.1.3 Bayer Hepatoma Cell Targeted Drug Product and Solutions
    • 2.1.4 Bayer Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Bayer Recent Developments and Future Plans
  • 2.2 Eisai
    • 2.2.1 Eisai Details
    • 2.2.2 Eisai Major Business
    • 2.2.3 Eisai Hepatoma Cell Targeted Drug Product and Solutions
    • 2.2.4 Eisai Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Eisai Recent Developments and Future Plans
  • 2.3 Zelgen
    • 2.3.1 Zelgen Details
    • 2.3.2 Zelgen Major Business
    • 2.3.3 Zelgen Hepatoma Cell Targeted Drug Product and Solutions
    • 2.3.4 Zelgen Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Zelgen Recent Developments and Future Plans
  • 2.4 Cipla
    • 2.4.1 Cipla Details
    • 2.4.2 Cipla Major Business
    • 2.4.3 Cipla Hepatoma Cell Targeted Drug Product and Solutions
    • 2.4.4 Cipla Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Cipla Recent Developments and Future Plans
  • 2.5 Natco Pharma
    • 2.5.1 Natco Pharma Details
    • 2.5.2 Natco Pharma Major Business
    • 2.5.3 Natco Pharma Hepatoma Cell Targeted Drug Product and Solutions
    • 2.5.4 Natco Pharma Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Natco Pharma Recent Developments and Future Plans
  • 2.6 BEACON Pharma
    • 2.6.1 BEACON Pharma Details
    • 2.6.2 BEACON Pharma Major Business
    • 2.6.3 BEACON Pharma Hepatoma Cell Targeted Drug Product and Solutions
    • 2.6.4 BEACON Pharma Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 BEACON Pharma Recent Developments and Future Plans
  • 2.7 Jiangxi Shanxiang
    • 2.7.1 Jiangxi Shanxiang Details
    • 2.7.2 Jiangxi Shanxiang Major Business
    • 2.7.3 Jiangxi Shanxiang Hepatoma Cell Targeted Drug Product and Solutions
    • 2.7.4 Jiangxi Shanxiang Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 Jiangxi Shanxiang Recent Developments and Future Plans
  • 2.8 Yao Pharma
    • 2.8.1 Yao Pharma Details
    • 2.8.2 Yao Pharma Major Business
    • 2.8.3 Yao Pharma Hepatoma Cell Targeted Drug Product and Solutions
    • 2.8.4 Yao Pharma Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Yao Pharma Recent Developments and Future Plans
  • 2.9 CSPC
    • 2.9.1 CSPC Details
    • 2.9.2 CSPC Major Business
    • 2.9.3 CSPC Hepatoma Cell Targeted Drug Product and Solutions
    • 2.9.4 CSPC Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.9.5 CSPC Recent Developments and Future Plans
  • 2.10 CHIATAI Tianqing
    • 2.10.1 CHIATAI Tianqing Details
    • 2.10.2 CHIATAI Tianqing Major Business
    • 2.10.3 CHIATAI Tianqing Hepatoma Cell Targeted Drug Product and Solutions
    • 2.10.4 CHIATAI Tianqing Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.10.5 CHIATAI Tianqing Recent Developments and Future Plans
  • 2.11 Simcere
    • 2.11.1 Simcere Details
    • 2.11.2 Simcere Major Business
    • 2.11.3 Simcere Hepatoma Cell Targeted Drug Product and Solutions
    • 2.11.4 Simcere Hepatoma Cell Targeted Drug Revenue, Gross Margin and Market Share (2020-2025)
    • 2.11.5 Simcere Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Hepatoma Cell Targeted Drug Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Hepatoma Cell Targeted Drug by Company Revenue
    • 3.2.2 Top 3 Hepatoma Cell Targeted Drug Players Market Share in 2024
    • 3.2.3 Top 6 Hepatoma Cell Targeted Drug Players Market Share in 2024
  • 3.3 Hepatoma Cell Targeted Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Hepatoma Cell Targeted Drug Market: Region Footprint
    • 3.3.2 Hepatoma Cell Targeted Drug Market: Company Product Type Footprint
    • 3.3.3 Hepatoma Cell Targeted Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Hepatoma Cell Targeted Drug Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Hepatoma Cell Targeted Drug Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Hepatoma Cell Targeted Drug Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Hepatoma Cell Targeted Drug Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Hepatoma Cell Targeted Drug Consumption Value by Type (2020-2031)
  • 6.2 North America Hepatoma Cell Targeted Drug Market Size by Application (2020-2031)
  • 6.3 North America Hepatoma Cell Targeted Drug Market Size by Country
    • 6.3.1 North America Hepatoma Cell Targeted Drug Consumption Value by Country (2020-2031)
    • 6.3.2 United States Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Hepatoma Cell Targeted Drug Consumption Value by Type (2020-2031)
  • 7.2 Europe Hepatoma Cell Targeted Drug Consumption Value by Application (2020-2031)
  • 7.3 Europe Hepatoma Cell Targeted Drug Market Size by Country
    • 7.3.1 Europe Hepatoma Cell Targeted Drug Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.3 France Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Hepatoma Cell Targeted Drug Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Hepatoma Cell Targeted Drug Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Hepatoma Cell Targeted Drug Market Size by Region
    • 8.3.1 Asia-Pacific Hepatoma Cell Targeted Drug Consumption Value by Region (2020-2031)
    • 8.3.2 China Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.5 India Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Hepatoma Cell Targeted Drug Consumption Value by Type (2020-2031)
  • 9.2 South America Hepatoma Cell Targeted Drug Consumption Value by Application (2020-2031)
  • 9.3 South America Hepatoma Cell Targeted Drug Market Size by Country
    • 9.3.1 South America Hepatoma Cell Targeted Drug Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Hepatoma Cell Targeted Drug Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Hepatoma Cell Targeted Drug Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Hepatoma Cell Targeted Drug Market Size by Country
    • 10.3.1 Middle East & Africa Hepatoma Cell Targeted Drug Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Hepatoma Cell Targeted Drug Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Hepatoma Cell Targeted Drug Market Drivers
  • 11.2 Hepatoma Cell Targeted Drug Market Restraints
  • 11.3 Hepatoma Cell Targeted Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Hepatoma Cell Targeted Drug Industry Chain
  • 12.2 Hepatoma Cell Targeted Drug Upstream Analysis
  • 12.3 Hepatoma Cell Targeted Drug Midstream Analysis
  • 12.4 Hepatoma Cell Targeted Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Hepatoma Cell Targeted Drug market size was valued at US$ 1005 million in 2024 and is forecast to a readjusted size of USD 1671 million by 2031 with a CAGR of 7.6% during review period.
    The most effective targeted drug introduced for HCC has been sorafenib. Sorafenib, a multi-tyrosine kinase inhibitor (TKI), remains the only systemic targeted tumor therapy in use for advanced HCC (18-21).
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Hepatoma Cell Targeted Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Hepatoma Cell Targeted Drug market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Hepatoma Cell Targeted Drug market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Hepatoma Cell Targeted Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Hepatoma Cell Targeted Drug market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Hepatoma Cell Targeted Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Hepatoma Cell Targeted Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Eisai, Zelgen, Cipla, Natco Pharma, BEACON Pharma, Jiangxi Shanxiang, Yao Pharma, CSPC, CHIATAI Tianqing, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Hepatoma Cell Targeted Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Sorafenib
    Lenvatinib
    Regorafenib
    Other
    Market segment by Application
    Hospital
    Retail Pharmacy
    Other
    Market segment by players, this report covers
    Bayer
    Eisai
    Zelgen
    Cipla
    Natco Pharma
    BEACON Pharma
    Jiangxi Shanxiang
    Yao Pharma
    CSPC
    CHIATAI Tianqing
    Simcere
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Hepatoma Cell Targeted Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Hepatoma Cell Targeted Drug, with revenue, gross margin, and global market share of Hepatoma Cell Targeted Drug from 2020 to 2025.
    Chapter 3, the Hepatoma Cell Targeted Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Hepatoma Cell Targeted Drug market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Hepatoma Cell Targeted Drug.
    Chapter 13, to describe Hepatoma Cell Targeted Drug research findings and conclusion.

    Buy now